1,25-dihydroxyvitamin D (1,25(OH)2 D) is a critical determinant of calcium (Ca) and phosphorus (Pi) metabolism and is essential for bone growth and mineralization. Renal mitochondrial 1-alpha hydroxylase (P450c1a) enzyme is the rate limiting step in the synthesis of the active form of vitamin D -1,25(OH)2D, and the hormone is inactivated by the enzyme 24-hydroxylase (P450c24) in the kidney and other tissues. Serum 1,25 OH)2D concentration is regulated by PTH, Ca, Pi and 1,25(OH)2 D primarily by regulation of the enzymes responsible for its synthesis and degradation. Disorders of vitamin D metabolism causes rickets in children and osteomalacia in adults due to abnormal bone mineralization. Fibroblast Growth Factor-23 (FGF- 23) is a circulating peptide, recently identified in a group of hypophosphatemic syndromes such as X-linked hypophosphatemic rickets (XLH) that is characterized by severe renal phosphate wasting, inappropriately low serum 1,25(OH)2D concentrations, and skeletal demineralization. FGF-23 has been shown to decrease serum 1,25(OH)2D concentrations by suppressing renal 1,25(OH)2D production. Evidence is emerging that FGF-23 is an important physiologic regulator of Pi, vitamin D, and bone metabolism, independent of PTH, and may play a role in abnormal bone and mineral homeostasis in chronic kidney disease. Much remains to be learnt about the actions of FGF-23 and the mechanisms by which it regulates vitamin D metabolism. We hypothesize that FGF-23 acts directly on the kidney to regulate P450c1a and P450c24 gene expression and thereby regulates renal 1,25(OH)2 D production. To test this hypothesis, we propose the following -Aims1&2: Determine the transcriptional and post-transcriptional mechanisms by which FGF-23 regulates P450c1a and P450c24 gene expression in human and mouse renal proximal tubule cell cultures.
Aim 3 : Characterize the signaling mechanisms by which FGF-23 regulates vitamin D metabolism in renal tubular cells in vitro and in wild type, Hyp (a murine model of XLH), and fgf-23 transgenic mice in vivo. This research proposal is aimed at advancing our current knowledge about vitamin D production in the kidney and provide novel insights in disease conditions where vitamin D synthesis is abnormal. Understanding how various factors control vitamin D production will provide new therapeutic strategies to treat bone disease in children with rickets, and in patients suffering from kidney failure.

Agency
National Institute of Health (NIH)
Institute
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Type
Clinical Investigator Award (CIA) (K08)
Project #
5K08DK073092-05
Application #
7905014
Study Section
Diabetes, Endocrinology and Metabolic Diseases B Subcommittee (DDK)
Program Officer
Rankin, Tracy L
Project Start
2006-09-01
Project End
2012-07-31
Budget Start
2010-08-01
Budget End
2012-07-31
Support Year
5
Fiscal Year
2010
Total Cost
$125,820
Indirect Cost
Name
University of California San Francisco
Department
Pediatrics
Type
Schools of Medicine
DUNS #
094878337
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Chanakul, Ankanee; Zhang, Martin Y H; Louw, Andrew et al. (2013) FGF-23 regulates CYP27B1 transcription in the kidney and in extra-renal tissues. PLoS One 8:e72816
Zhang, Martin Y H; Ranch, Daniel; Pereira, Renata C et al. (2012) Chronic inhibition of ERK1/2 signaling improves disordered bone and mineral metabolism in hypophosphatemic (Hyp) mice. Endocrinology 153:1806-16
Ranch, Daniel; Zhang, Martin Yh; Portale, Anthony A et al. (2011) Fibroblast growth factor 23 regulates renal 1,25-dihydroxyvitamin D and phosphate metabolism via the MAP kinase signaling pathway in Hyp mice. J Bone Miner Res 26:1883-90